-
The sale of a stake in Harmony Hospital by Fosun Pharma's subsidiary has been completed
Time of Update: 2021-03-04
are the limited partnership interests of Harmony Hospitals and Clinics) and shares in Healthy Harmony GP, Inc. ("Healthy Harmony GP"), a managing partner of HHH. Of the approximately $523.15 million
-
Chongqing Pharma acquired an 87.47% stake in the subsidiary
Time of Update: 2021-03-04
On December 16, Tiansli announced that it had signed a Framework Agreement with Chongqing Pharmaceuticals (Group) Co., Ltd.
-
Asasin Pharma won the 10th FDA Orphan Drug Certification, and Bcl-2 inhibitor APG-2575 added one
Time of Update: 2021-03-03
HK) announced today that the U.S. Food and Drug Administration (FDA) has awarded the company the qualification of the original innovative drug Bcl-2 inhibitor APG-2575 orphan drug for the treatment of fable lymphoma (FL).
-
CRO track all skyrocketed, Tag pharma, Kanglong into a 10% increase
Time of Update: 2021-03-02
research organization is an academic or commercial scientific institution or individual that conducts all or part of a customer's scientific or medical trials in the course of drug development for commercial gain. The CRO
-
Merck Pharma holding hands with Ali Health Path-to-Road Pharmaceutical e-commerce
Time of Update: 2021-02-28
the people's growing multi-level diversified medical and health needs, in April this year, the General Office of the State Council issued the Opinions on Promoting the Development of "Internet plus Medical Health", which is another heavyweight top-level
-
Fosun Pharma's net profit decreased by 13.44% in the first three quarters
Time of Update: 2021-02-27
Fosun Pharma explained the decline in net profit in its third-quarter report, saying it was mainly affected by higher investment in innovative research and development and business layout, losses at some participating companies and higher interest expense.
-
Artios Pharma has raised more than 65 million pounds to develop DDR therapy
Time of Update: 2021-02-22
Cambridge-based Artios Pharma Biotech has raised more than 65 million pounds in round B financing from investors including Pfizer and Novaral to further develop DNA Damage Response (DDR) cancer treatments.
-
Tiger Pharma: Subsidiary and Kyusek Pharmaceuticals established the United States FJ Company to provide drug research and development one-stop service
Time of Update: 2021-02-22
Tiger Pharma announced on the evening of January 24th that Frontage Laboratories, Inc., a subsidiary of the company, had announced that it would not be in a company that would be in a state of force. ("Fangda Pharmaceuticals") recently signed
-
Mercer East's $1.25 billion acquisition of Afferent Pharma
Time of Update: 2021-02-22
a final deal has been reached after US pharmaceutical giant Merck and Co announced a $1.25bn takeover of Afferent Pharma. The deal is expected to be completed in the third quarter of this year. Afferent Pharma is a privately held
-
1.26 billion U.S. dollars holding Indian pharmaceutical company Fosun Pharma accelerated internationalization
Time of Update: 2021-02-21
wholly-owned subsidiary FOSUNPHARMAINDUSTRIALPTE.LTD. (here referred to as the acquirer), Fosun Industrial (Hong Kong) Co., Ltd. (the joint acquirer) and Gland's existing shareholders and related parties signed the relevant agreement on the 28th. Data
-
$80 million Fosun Pharma teamed up with Kite Pharma to advance immunotherapy
Time of Update: 2021-02-21
Fosun Pharma, the capital-run company, has launched a new round of "invest, buy and buy" in 2017, targeting the CAR-T cell immunotherapy market for the first time. and Kite Pharma (NASDAQ: KITE) Co., Ltd. jointly set up a Sino-foreign
-
Fosun Pharma's 3 innovative drugs have been approved for clinical lyxidan resistance and are expected to challenge Roche
Time of Update: 2021-02-19
review publicity list, which means that the domestic first biosychlic drug market into the final sprint stage. At present, the domestic listing of lysoxi single anti-injection only Shanghai Roche Pharmaceutical Co., Ltd.'s Merivale. According
-
Shanghai Pharma intends to purchase Kantre's China business plus the field of pharmaceutical circulation
Time of Update: 2021-02-19
pharmaceutical distribution giant Cardinal Health Inc. (hereinafter referred to as Kantle China) and said it had made two rounds of offers. There are industry insiders to the "Daily Economic News" reporter analysis that Kantle China in the chain
-
Fosun Pharma: Medical service layout next city buy rating
Time of Update: 2021-02-19
Investment Point Company announced on December 8th that Fosun Hospital, the company's controlling subsidiary, had signed the Investment Cooperation Framework Agreement with Zigong City Mental Health Center to reach a cooperation intention
-
Fish Leap Medical's 550 million yuan acquisition of 38.38 percent of China Excellent Pharma's shares to achieve full control
Time of Update: 2021-02-19
According to incomplete statistics of The New Kangjie, in 2017 Fish Leap Medical acquired stakes in four enterprises and participated in the launch and subscription of two medical industry mergers and acquisitions funds.
-
Shanghai Pharma: The commercial expansion is steadily advancing in the buy rating
Time of Update: 2021-02-19
Shanghai Pharma completed the acquisition and delivery of Kantle's China business on February 2nd, the company announced the completion of the acquisition of Kantle Malaysia, with a final purchase price of $576 million. Upon completion
-
The FDA grants fast-track qualification to Fosun Pharma ORIN1001
Time of Update: 2021-02-16
founded in July 2017 by a team of Fosun Pharma and overseas scientists, Fosun has established research and development bases in Suzhou and Los Angeles, focusing on anti-cancer drugs related to the metabolism of small molecules and cancer cells.
-
Following Merca East, Arno Pharma joins hands with Roche! Cooperate in the exploration of its two products in the study and PD-L1 monoantial joint drug use
Time of Update: 2021-02-01
of this study was to determine the appropriate dose for both dose-limiting toxicity (DLT) and at the same time as attilijudant. the dose finding (DLT) part, the purpose of the trial was to study the safety and effectiveness of triple drug use in patients
-
Fosun Pharma: Recombinant anti-CD38 all-human monoclonal antibody injections have been approved in clinical trials
Time of Update: 2021-01-31
the new drug is the Group (i.e., the Company and its controlling subsidiaries/units, the same between 2) independently developed Daretoyu monoclonal antibody biosynthesis drug, intended for the treatment of multiple myeloma.
-
Fosun Pharma "long-acting Botox" starts Phase III clinically
Time of Update: 2021-01-31
insight database shows that the new drug for moderate to severe eyebrow tattoo therapy is still in the U.S. FDA listing application stage, for neck dystain disorder treatment in the U.S. in Phase III clinical trials.
